1. Home
  2. EPRT vs NUVL Comparison

EPRT vs NUVL Comparison

Compare EPRT & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Essential Properties Realty Trust Inc.

EPRT

Essential Properties Realty Trust Inc.

HOLD

Current Price

$30.14

Market Cap

6.6B

Sector

Real Estate

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$88.16

Market Cap

7.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPRT
NUVL
Founded
2016
2017
Country
United States
United States
Employees
N/A
228
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
7.2B
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
EPRT
NUVL
Price
$30.14
$88.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
16
Target Price
$36.79
$134.75
AVG Volume (30 Days)
1.3M
757.8K
Earning Date
04-22-2026
05-08-2026
Dividend Yield
3.98%
N/A
EPS Growth
11.30
N/A
EPS
0.28
N/A
Revenue
$561,219,000.00
N/A
Revenue This Year
$17.12
N/A
Revenue Next Year
$16.27
$1,239.49
P/E Ratio
$108.11
N/A
Revenue Growth
24.82
N/A
52 Week Low
$28.95
$71.14
52 Week High
$34.73
$113.02

Technical Indicators

Market Signals
Indicator
EPRT
NUVL
Relative Strength Index (RSI) 39.73 34.83
Support Level $29.24 $74.80
Resistance Level $30.39 $109.45
Average True Range (ATR) 0.52 4.73
MACD -0.08 -1.67
Stochastic Oscillator 28.04 3.63

Price Performance

Historical Comparison
EPRT
NUVL

About EPRT Essential Properties Realty Trust Inc.

Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: